Ensysce Biosciences Inc. (ENSC)
Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection
Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection
📈 **POSITIVE** • Medium confidence analysis (61%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (84%) **Content type:** Clinical